237 related articles for article (PubMed ID: 28017790)
1. The CB1 receptor is required for the establishment of the hyperlocomotor phenotype in developmentally-induced hypothyroidism in mice.
Giné E; Echeverry-Alzate V; Lopez-Moreno JA; Rodriguez de Fonseca F; Perez-Castillo A; Santos A
Neuropharmacology; 2017 Apr; 116():132-141. PubMed ID: 28017790
[TBL] [Abstract][Full Text] [Related]
2. Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors.
Martín AB; Fernandez-Espejo E; Ferrer B; Gorriti MA; Bilbao A; Navarro M; Rodriguez de Fonseca F; Moratalla R
Neuropsychopharmacology; 2008 Jun; 33(7):1667-79. PubMed ID: 17957223
[TBL] [Abstract][Full Text] [Related]
3. Requirement for the endocannabinoid system in social interaction impairment induced by coactivation of dopamine D1 and D2 receptors in the piriform cortex.
Zenko M; Zhu Y; Dremencov E; Ren W; Xu L; Zhang X
J Neurosci Res; 2011 Aug; 89(8):1245-58. PubMed ID: 21557291
[TBL] [Abstract][Full Text] [Related]
4. Genetic deletion of dopamine D1 receptors increases the sensitivity to cannabinoid CB1 receptor antagonist-precipitated withdrawal when compared with wild-type littermates: studies in female mice repeatedly exposed to the Spice cannabinoid HU-210.
Serrano A; Vadas E; Ferrer B; Bilbao A; Granado N; Suárez J; Pavon FJ; Moratalla R; Rodríguez de Fonseca F
Psychopharmacology (Berl); 2021 Feb; 238(2):551-557. PubMed ID: 33410990
[TBL] [Abstract][Full Text] [Related]
5. Genetic or pharmacological depletion of cannabinoid CB1 receptor protects against dopaminergic neurotoxicity induced by methamphetamine in mice.
Dang DK; Shin EJ; Mai AT; Jang CG; Nah SY; Jeong JH; Ledent C; Yamamoto T; Nabeshima T; Onaivi ES; Kim HC
Free Radic Biol Med; 2017 Jul; 108():204-224. PubMed ID: 28363605
[TBL] [Abstract][Full Text] [Related]
6. Modulation of the effects of the cannabinoid agonist, ACPA, on spatial and non-spatial novelty detection in mice by dopamine D1 receptor drugs infused into the basolateral amygdala.
Mohammadi M; Nasehi M; Zarrindast MR
Behav Brain Res; 2015 Mar; 280():36-44. PubMed ID: 25476564
[TBL] [Abstract][Full Text] [Related]
7. Dopamine D1 and D2 agonist effects on prepulse inhibition and locomotion: comparison of Sprague-Dawley rats to Swiss-Webster, 129X1/SvJ, C57BL/6J, and DBA/2J mice.
Ralph RJ; Caine SB
J Pharmacol Exp Ther; 2005 Feb; 312(2):733-41. PubMed ID: 15494551
[TBL] [Abstract][Full Text] [Related]
8. CB1 receptor knockout mice display reduced ethanol-induced conditioned place preference and increased striatal dopamine D2 receptors.
Houchi H; Babovic D; Pierrefiche O; Ledent C; Daoust M; Naassila M
Neuropsychopharmacology; 2005 Feb; 30(2):339-49. PubMed ID: 15383833
[TBL] [Abstract][Full Text] [Related]
9. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum.
Giuffrida A; Parsons LH; Kerr TM; Rodríguez de Fonseca F; Navarro M; Piomelli D
Nat Neurosci; 1999 Apr; 2(4):358-63. PubMed ID: 10204543
[TBL] [Abstract][Full Text] [Related]
10. The Ras homolog Rhes affects dopamine D1 and D2 receptor-mediated behavior in mice.
Quintero GC; Spano D; Lahoste GJ; Harrison LM
Neuroreport; 2008 Oct; 19(16):1563-6. PubMed ID: 18845937
[TBL] [Abstract][Full Text] [Related]
11. Opposite function of dopamine D1 and N-methyl-D-aspartate receptors in striatal cannabinoid-mediated signaling.
Daigle TL; Wetsel WC; Caron MG
Eur J Neurosci; 2011 Nov; 34(9):1378-89. PubMed ID: 22034973
[TBL] [Abstract][Full Text] [Related]
12. CB1 cannabinoid receptor-mediated increases in cyclic AMP accumulation are correlated with reduced Gi/o function.
Eldeeb K; Leone-Kabler S; Howlett AC
J Basic Clin Physiol Pharmacol; 2016 May; 27(3):311-22. PubMed ID: 27089415
[TBL] [Abstract][Full Text] [Related]
13. Evidence against dopamine D1/D2 receptor heteromers.
Frederick AL; Yano H; Trifilieff P; Vishwasrao HD; Biezonski D; Mészáros J; Urizar E; Sibley DR; Kellendonk C; Sonntag KC; Graham DL; Colbran RJ; Stanwood GD; Javitch JA
Mol Psychiatry; 2015 Nov; 20(11):1373-85. PubMed ID: 25560761
[TBL] [Abstract][Full Text] [Related]
14. Dopaminergic brain system in the quaking mutant mouse.
Nikulina EM; Skrinskaya JA; Avgustinovich DF; Popova NK
Pharmacol Biochem Behav; 1995 Mar; 50(3):333-7. PubMed ID: 7617670
[TBL] [Abstract][Full Text] [Related]
15. Cannabinoid CB1 receptor antagonism markedly increases dopamine receptor-mediated stereotypies.
Ferrer B; Gorriti MA; Palomino A; Gornemann I; de Diego Y; Bermudez-Silva FJ; Bilbao A; Fernandez-Espejo E; Moratalla R; Navarro M; Rodríguez de Fonseca F
Eur J Pharmacol; 2007 Mar; 559(2-3):180-3. PubMed ID: 17291487
[TBL] [Abstract][Full Text] [Related]
16. Dopamine-D1 and -D2 receptors differentially regulate synapsin II expression in the rat brain.
Chong VZ; Skoblenick K; Morin F; Xu Y; Mishra RK
Neuroscience; 2006; 138(2):587-99. PubMed ID: 16413126
[TBL] [Abstract][Full Text] [Related]
17. Endogenous and synthetic cannabinoids induce the downregulation of cannabinoid CB1 receptor in retina.
Papadogkonaki S; Theodorakis Κ; Thermos K
Exp Eye Res; 2019 Aug; 185():107694. PubMed ID: 31199905
[TBL] [Abstract][Full Text] [Related]
18. Implication of the endocannabinoid system in the locomotor hyperactivity associated with congenital hypothyroidism.
Asúa T; Bilbao A; Gorriti MA; Lopez-Moreno JA; Del Mar Alvarez M; Navarro M; Rodríguez de Fonseca F; Perez-Castillo A; Santos A
Endocrinology; 2008 May; 149(5):2657-66. PubMed ID: 18218697
[TBL] [Abstract][Full Text] [Related]
19. Cannabinoid-induced depression of synaptic transmission is switched to stimulation when dopaminergic tone is increased in the globus pallidus of the rodent.
Caballero-Florán RN; Conde-Rojas I; Oviedo Chávez A; Cortes-Calleja H; Lopez-Santiago LF; Isom LL; Aceves J; Erlij D; Florán B
Neuropharmacology; 2016 Nov; 110(Pt A):407-418. PubMed ID: 27506997
[TBL] [Abstract][Full Text] [Related]
20. Dopamine-dependent CB1 receptor dysfunction at corticostriatal synapses in homozygous PINK1 knockout mice.
Madeo G; Schirinzi T; Maltese M; Martella G; Rapino C; Fezza F; Mastrangelo N; Bonsi P; Maccarrone M; Pisani A
Neuropharmacology; 2016 Feb; 101():460-70. PubMed ID: 26498506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
